Dr. Anuradha Krishnamurthy
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Studies Colorectal Cancer
Studies Cancer
18 reported clinical trials
32 drugs studied
About Anuradha Krishnamurthy
Education:
- Obtained MD from the University of Pittsburgh School of Medicine in 2008.
- Completed Residency in Internal Medicine at the University of Pittsburgh Medical Center (2008-2011).
- Undertook Fellowship in Hematology/Oncology at the University of Pittsburgh Medical Center (2011-2014).
Experience:
- Faculty member at the University of Pittsburgh School of Medicine, specializing in hematology and oncology.
- Clinical interests focus on breast cancer, gastrointestinal cancers, and genitourinary malignancies.
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
Stage II
2Cancer
Stage IV
SETD2 positive
Mismatch Repair Deficiency positive
Affiliated Hospitals
Clinical Trials Anuradha Krishnamurthy is currently running
BRAF-Targeted Therapy
for Colon Cancer
This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.
Recruiting1 award Phase 2 & 3
CTX-8371
for Advanced Cancer
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Recruiting1 award Phase 1
More about Anuradha Krishnamurthy
Clinical Trial Related4 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Anuradha Krishnamurthy has experience with
- Fluorouracil
- Cetuximab
- Nivolumab
- Ipilimumab
- Oxaliplatin
- Bevacizumab
Breakdown of trials Anuradha Krishnamurthy has run
Colorectal Cancer
Cancer
Adenocarcinoma
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anuradha Krishnamurthy specialize in?
Anuradha Krishnamurthy focuses on Colorectal Cancer and Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Anuradha Krishnamurthy currently recruiting for clinical trials?
Yes, Anuradha Krishnamurthy is currently recruiting for 4 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Anuradha Krishnamurthy has studied deeply?
Yes, Anuradha Krishnamurthy has studied treatments such as Fluorouracil, Cetuximab, Nivolumab.
What is the best way to schedule an appointment with Anuradha Krishnamurthy?
Apply for one of the trials that Anuradha Krishnamurthy is conducting.
What is the office address of Anuradha Krishnamurthy?
The office of Anuradha Krishnamurthy is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.